7-6009017-C-T
Variant summary
Our verdict is Pathogenic. Variant got 20 ACMG points: 20P and 0B. PVS1PS1_ModeratePM2PP5_Very_Strong
The NM_000535.7(PMS2):c.3G>A(p.Met1?) variant causes a start lost change. The variant allele was found at a frequency of 0.000000685 in 1,460,248 control chromosomes in the GnomAD database, with no homozygous occurrence. In-silico tool predicts a pathogenic outcome for this variant. Variant has been reported in ClinVar as Pathogenic (★★).
Frequency
Consequence
NM_000535.7 start_lost
Scores
Clinical Significance
Conservation
Genome browser will be placed here
ACMG classification
Verdict is Pathogenic. Variant got 20 ACMG points.
Transcripts
RefSeq
Ensembl
Frequencies
GnomAD3 genomes Cov.: 32
GnomAD4 exome AF: 6.85e-7 AC: 1AN: 1460248Hom.: 0 Cov.: 32 AF XY: 0.00000138 AC XY: 1AN XY: 726436
GnomAD4 genome Cov.: 32
ClinVar
Submissions by phenotype
Hereditary cancer-predisposing syndrome Pathogenic:2
The p.M1? pathogenic mutation (also known as c.3G>A), located in coding exon 1 of the PMS2 gene and results from a G to A substitution at nucleotide position 3. This alters the methionine residue at the initiation codon (ATG). Sequence variations that modify the initiation codon are expected to result in either loss of translation initiation, N-terminal truncation, or cause a shift in the mRNA reading frame. Based on the supporting evidence, this alteration is interpreted as a disease-causing mutation. -
This variant results in the loss of the translation start codon (methionine at codon 1) of the PMS2 gene. This variant is expected to disrupt the expression of the full-length PMS2 protein. The next in-frame methionine occurs at codon 136, and it is not known if a functional PMS2 protein product can be produced using p.Met136 as an alternative translation start site. To our knowledge, functional studies have not been reported for this variant. This nucleotide change has not been reported in the literature, however, other variants resulting in a start loss at codon 1 have been observed in individuals affected with Lynch syndrome-associated disease (ClinVar ID: 91323, 142777, 182809). This variant has not been identified in the general population by the Genome Aggregation Database (gnomAD). Based on the available evidence, this variant is classified as Pathogenic. -
not provided Pathogenic:1
Initiation codon variant in a gene for which loss-of-function is a known mechanism of disease; Not observed in large population cohorts (Lek et al., 2016); This variant is associated with the following publications: (PMID: 29485237, 28514183, 28466842, 27742654) -
Hereditary nonpolyposis colorectal neoplasms Pathogenic:1
This sequence change affects the initiator methionine of the PMS2 mRNA. The next in-frame methionine is located at codon 136. This variant is not present in population databases (gnomAD no frequency). Disruption of the initiator codon has been observed in individual(s) with clinical features of Lynch syndrome and/or constitutional mismatch repair deficiency syndrome (PMID: 18602922, 20487569, 23709753, 27476653). In at least one individual the data is consistent with being in trans (on the opposite chromosome) from a pathogenic variant. ClinVar contains an entry for this variant (Variation ID: 450786). For these reasons, this variant has been classified as Pathogenic. -
Lynch syndrome 4 Pathogenic:1
This variant is considered pathogenic. This variant is located within the gene translation start codon (p.Met1?) and is predicted to result in abnormal protein translation. This variant has been reported in multiple individuals with clinical features of gene-specific disease [PMID: 30680046, 27476653, 18602922]. -
Computational scores
Source:
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at